Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...
The technical picture worsened for Eli Lilly stock in December as it completed a pattern known as a “Death Cross”. This ...
Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...
Eli Lilly (LLY 1.45%) began a roll in late 2020 that lasted almost four years. During that time, it became the world's ...
Novo Nordisk just got a reality check. The company's latest trial for a higher-dose Wegovy showed it helps patients shed more ...
Weight loss goals may be at the forefront of many New Year's resolutions, which could push the exuberance for Eli Lilly LLY ...
Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...
Argus lowered the firm’s price target on Novo Nordisk (NVO) to $110 from $140 but keeps a Buy rating on the shares and contends that the ...
In my opinion, Novo Nordisk (NVO) stock offers the former, while Eli Lilly (LLY) stock offers the latter. NVO stock may achieve better one-year returns due to its undervaluation, but LLY stock ...
Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a ...
Interestingly, celebrities like Elon Musk, Oprah Winfrey and Amy Schumer, among others, have also endorsed drugs like Ozempic ...